Y-90 Radioembolization Now Offered in an Outpatient Setting
Kansas City, Kan. ― The University of Kansas Health System now offers radioembolization, also known as Y-90, as an outpatient procedure at The University of Kansas Hospital in Overland Park. Our fellowship-trained interventional radiologists speciali...
Cancer Program Recognized Among Nation’s Top 10 Percent
U.S. News & World Report released its 2020-21 Best Hospitals rankings on July 28. The cancer program at The University of Kansas Hospital is recognized among the top 10% of all hospitals in the nation. U.S. News evaluates hospitals on a series of a...
Ronald Chen named a Fellow of the American Society for Radiation Oncology
Honor recognizes exceptional service to the field of radiation oncology and cancer care
Targeting telomerase to slow cancer growth
Graduate student Matthew Schaich forges ahead with research efforts, career aspirations, despite added challenges of pandemic.
KU Cancer Center highlights from AACR Annual Meeting
The meeting featured a variety of sessions including a Clinical Plenary session, led by Weijing Sun, MD, director of Medical Oncology.
Chen Elected Co-Chair of NCI's Prostate Cancer Task Force
Task force is guided by strategic priorities, include addressing areas of unmet clinical need, unanswered clinical questions and potential new approaches to disease treatment.
KU Cancer Center at ASCO
More than 42,750 people from 138 countries attended this year’s American Society of Clinical Oncology (ASCO) annual meeting. Held virtually for the first time ever, the meeting featured 2,600 faculty and speakers and 5,300 abstracts delivering the latest news in cancer research. Members of The University of Kansas Cancer Center discussed their key findings and presented dozens of abstracts.
Novel Lab-on-a-Chip Detects Breast Cancer Metastasis Earlier
A tiny tool developed by researchers could help detect and track the spread of tumors in breast cancer patients.
First Patient Treated in Gamma-Delta T Cell Immunotherapy Phase I Study
Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced that the first patient in a phase I clinical study, Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide, has been treated at The University of Kansas Cancer Center.
Cancer Center Pivots to Protect Patients and Trial Participants Amidst Pandemic
Research arm provides COVID-19 testing for more than 500 cancer patients
Joan W. Conaway elected to National Academy of Sciences
Dr. Conaway has been elected for her distinguished and continuing achievements in original scientific research. Membership in the NAS is considered one of the highest honors given to a scientist in the United States.
Chen Appointed NRG Oncology Principal Investigator
Ronald Chen, MD, MPH, Brandmeyer Chair and Professor of Radiation Oncology, has been named the new principal investigator for NRG Oncology clinical trials efforts at The University of Kansas Cancer Center. He takes the place of Joshua Mammen, MD, PhD, FACS, division chief of Surgical Oncology, who served in the position for several years.
Ronald Chen Elected as Fellow to American Society of Clinical Oncology
The distinction is given to those who have carried out efforts that benefit ASCO, the specialty of oncology and the patients they serve.
Expert Panel Discusses Metastatic Breast Cancer Therapy Options
KU Cancer Center researcher participates in virtual peer-to-peer panel on expanding treatment opportunities